Actical Tablet 1200 mg+0.25 mcg

Actical Tablet combines Calcium Citrate + Calcitriol (1200 mg + 0.25 mcg) to address calcium and vitamin D deficiencies. Manufactured by ACI Limited, this tablet formulation helps prevent/treat hypocalcemia-related conditions like osteoporosis, osteomalacia, and hypoparathyroidism. Priced at ৳13.00 per unit, it offers cost-effective bone health management.

The medication enhances calcium absorption through synergistic action: calcium citrate requires no stomach acid for uptake, while calcitriol (active vitamin D₃) improves intestinal calcium transport. Ideal for postmenopausal women and renal patients, it reduces fracture risks by maintaining optimal bone mineralization. Dosage ranges from 1-4 tablets daily with/without food.

Key precautions include avoiding concurrent use with tetracyclines or aluminum products. Common side effects like constipation or nausea are generally mild. Patients should monitor calcium levels to prevent hypercalcemia, especially when using thiazide diuretics. Store below 25°C in airtight containers to maintain potency.

As a specific mineral & vitamin combination, Actical Tablet stands out among calcium supplements for its enhanced bioavailability. Consult doctors for personalized dosing during pregnancy or lactation (Category C). Explore ACI Limited’s full pharmaceutical range for complementary therapies.

1-4 tablets daily as directed by physician, taken with/without food. Dose adjustment required in renal impairment. Treatment duration depends on disease severity and serum calcium monitoring.

The side efects of Actical are-constipation, nausea, abdominal pain, hypercalcaemia, hypercalciuria, headache, muscle weakness.

Pregnancy Category C: Potential fetal risk in animal studies. Use during lactation only under medical supervision. Calcium may excreted in breast milk.

Monitor calcium-phosphate levels in cardiac/renal patients. Sarcoidosis increases hypercalcemia susceptibility. Follow manufacturer guidelines for safe use.

Geriatric patients may require dose reduction based on renal function. Pediatric safety unestablished. Hepatic/renal impairment necessitates dosage adjustment.